SCHEMBL30588194

SCHEMBL30588194

CC(C)(C)OC(=O)N1CCC(n2ccc3c(I)c(F)ccc32)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCG P05129 1/20 0.45
▸ PRKCB P05771 1/20 0.45
▸ PRKCA P17252 1/20 0.45
▸ PRKCH P24723 1/20 0.45
▸ PRKCE Q02156 1/20 0.45
▸ PRKCD Q05655 1/20 0.45
▸ GPR119 Q8TDV5 8/20 0.43
▸ HCAR1 Q9BXC0 1/20 0.43
▸ DPP4 P27487 1/20 0.43
▸ NR3C1 P04150 1/20 0.42
▸ TP53 P04637 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ PTPN2 P17706 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ PTPN6 P29350 1/20 0.41
▸ TRPV3 Q8NET8 1/20 0.40
▸ CTSD P07339 1/20 0.40
▸ CTSE P14091 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26118195 1.00 PRKCG (0.45) PRKCGPRKCBPRKCAPRKCHPRKCE
SCHEMBL26115203 0.83 MEN1 (0.34) KDM4E
SCHEMBL25337226 0.78 PRKCG (0.51) PRKCGPRKCBPRKCAPRKCHPRKCE
SCHEMBL25939069 0.78 PRKCG (0.51) PRKCGPRKCBPRKCAPRKCHPRKCE
SCHEMBL31386049 0.77 GPR119 (0.40) PRKCGPRKCBPRKCAPRKCHPRKCE
SCHEMBL27268992 0.77 PRKCG (0.46) PRKCGPRKCBPRKCAPRKCHPRKCE
SCHEMBL30962038 0.77 PRKCG (0.46) PRKCGPRKCBPRKCAPRKCHPRKCE
SCHEMBL12471639 0.76 HCAR1 (0.43) PRKCGPRKCBPRKCAPRKCHPRKCE
SCHEMBL30588286 0.76 HCAR1 (0.48) PRKCGPRKCBPRKCAPRKCHPRKCE
SCHEMBL26119513 0.76 HCAR1 (0.48) PRKCGPRKCBPRKCAPRKCHPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577231-B2 Androgen receptor PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-03-17 — — US disclosed
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-01 — — US disclosed
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-06-26 — — US disclosed
WO-2025061906-A1 ANDROGEN RECEPTOR PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-03-27 — — WO disclosed
EP-4499628-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-02-05 — — EP disclosed
WO-2023180388-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS AR, CRBN, PSMA3 PRKCG 1451/4885PRKCB 1597/4885PRKCA 1935/4885
US-12577231-B2 Androgen receptor PROTACS AR, CRBN, PSMA3 PRKCG 1451/4885PRKCB 1597/4885PRKCA 1935/4885
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS CRBN, AR, GNRHR PRKCG 2292/4885PRKCB 2927/4885PRKCA 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback